Please visit
https://sites.google.com/view/chemotimelines2025/
to learn about our 2025 version of the shared task
Chemotherapy Treatment Timelines Extraction
from the Clinical Narrative
(last update June 17, 2025)
Please visit
https://sites.google.com/view/chemotimelines2025/
to learn about our 2025 version of the shared task
Chemotherapy Treatment Timelines Extraction
from the Clinical Narrative
(last update June 17, 2025)
Treatment regimens are key details in understanding the effects of genetic, epigenetic, and other factors on tumor behavior and responsiveness. As precision oncology progresses, insights into the fine interplay of treatment with tumor molecular characteristics and patient phenotypes becomes even more critical not only as a source of research data, but as a means of translating findings into patient-tailored therapies similar to those that have been applied to breast cancer and melanoma.
The goal of this task is to build a timeline of chemotherapy treatment for each patient given all the available Electronic Health Records (EHR) notes of that patient. The notes range the entire spectrum -- primary care provider, oncology, discharge summaries, emergency department, pathology, radiology, etc. Success in completing this task will provide previously unavailable tools for extracting timelines for contextualizing cancer treatment.
Due dates listed below are end of each day (23:59:59), Anywhere on Earth (AoE: UTC-12).
Jan 8, 2024: Registration opens (including Data Use Agreement process)
Jan 26, 2024: Training and validation data release (see Registration and Data Access on instructions regarding getting access to the data with a signed Data Use Agreement)
March 26, 2024 (was Feb 26, 2024): Test data release date (see information under Data)
March 28, 2024 (was March 1, 2024): Run submission due (see information under Submission of Test Output)
April 1, 2024 (was March 6, 2024): Release of the results by the organizers
April 8, 2024: Shared task paper submission period starts
April 10, 2024 (was March 19, 2024): Paper submission due
April 18, 2024 (was April 16, 2024): Notification of acceptance
April 24, 2024: Final versions of papers due
June 21, 2024: Workshop @ NAACL 2024, Mexico City, Mexico
Registration opens: Jan 8, 2024 - Closed!
To register for the task, please fill out the form. Note that because the data is de-identified EHR notes of real patients, the Principal Investigator (PI) of each team has to sign a Data Use Agreement (DUA).
Jiarui Yao, Boston Children’s Hospital/Harvard Medical School
Guergana Savova, Boston Children’s Hospital/Harvard Medical School
Harry Hochheiser, University of Pittsburgh
WonJin Yoon, Boston Children’s Hospital/Harvard Medical School
Eli Goldner, Boston Children’s Hospital/Harvard Medical School
For general communications: Please, use our google group ChemoTimelines2024 (https://groups.google.com/g/chemotimelines2024)
When joining the group, please indicate your name and affiliation in "Reason for Joining" section.
This forum is a place for any questions you may have about the shared task. Please post your questions here, except in the specific case outlined below, so that all participants can benefit from the information. Any emails sent directly to the organizers regarding the shared task may be shared with the Google group.
All email regarding data distribution will be sent to your Principal Investigator's email. Please, check that address regularly.
We request you refrain from posting any part of the task data in the google group ChemoTimelines2024, as it is possible to join the group before the Data Use Agreement (DUA) is fully executed.
Sensitive inquiries such as DUA, legal issues, data issues (e.g. de-identification), or deadlines can be sent to the organizers mailing list to organizers-chemoTimelines [at] googlegroups.com
Funding is provided by the United States National Institutes of Health (grants U24CA248010, R01LM010090, R01LM013486, R01LM012973, R01MH126977). The content is solely the responsibility of the authors and does not necessarily represent the official views of the United States National Institutes of Health.